Document is current
Any future updates will be listed below
-
Authors
Lopes, Snehal S.
Pericot-Valverde, Irene
Lum, Paula J.
Taylor, Lynn E.
Mehta, Shruti H.
Tsui, Judith I.
Feinberg, Judith
Kim, Arthur Y.
Norton, Brianna L.
Page, Kimberly
Murray-Krezan, Cristina
Anderson, Jessica
Karasz, Alison
Arnsten, Julia
Moschella, Phillip
Heo, Moonseong
Litwin, Alain H.
-
Funding
Funding for this research was provided by:
Patient-Centered Outcomes Research Institute (HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122, HPC-1503-28122)
Gilead Sciences
- License Information
-
More Information
Article History
Received: 29 November 2023
Accepted: 12 February 2024
First Online: 23 February 2024
Declarations
:
: The HERO study was approved by the IRBs at each of the study sites listed below, and informed consent to participate was obtained from all study participants.(1) West Virginia University: 1609287809(2) Brown University: 901973-2, 3(3) John Hopkins: 00007239(4) Massachusetts General Hospital: 2016P002442/PHS(5) Montefiore Medical Center: 2015-5723(6) University of California, San Francisco: 16-20016(7) University of New Mexico: 16-235(8) University of Washington: STUDY00002659
: Not Applicable.
: JF has received research grant support from Gilead Sciences. AYK has served on advisory boards for Biomarin. AHL has served on advisory boards for Gilead Sciences and Merck Pharmaceuticals and received research funding from Gilead Sciences. SHM has received speaker fees from Gilead Sciences. All other authors declare no competing interests.
